Dancs Peter T, Saner Fuat H, Benkö Tamas, Molmenti Ernesto P, Büchter Matthias, Paul Andreas, Hoyer Dieter P
General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany.
Department of Surgery, Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, NY, United States.
Front Surg. 2022 Mar 4;9:853727. doi: 10.3389/fsurg.2022.853727. eCollection 2022.
Current allocation mechanisms for liver transplantation (LT) overemphasize emergency, leading to poorer longtime outcomes. The utility was introduced to recognized outcomes in allocation. Recently, Molinari proposed a predictive outcome model based on recipient data.
The aims of this study were to validate this model and to combine it with the utility to emphasize outcome in allocation.
We retrospectively analyzed 734 patients who were transplanted between January 2010 and December 2019. Points were assigned as in Molinari's model and the score sum was correlated with observed 90-day mortality. The utility was calculated as the product of 1-year survival times 3-month mortality on the waiting list. The weighting of different compounds was introduced, and utility curves were calculated. Model for End-Stage Liver Disease (MELD) scores according to maximal utility were determined.
In total, 120 patients (16.3%) had died within 90 days after LT. Higher MELD score, obesity, and hemodialysis prior to LT were confirmed risk factors. Overall survival was 83.8 and 77.4% after 90 days and 12 months, respectively. General utility culminated at MELD scores >35 in the overall population. Emphasizing the outcome shifted the maximal utility to lower MELD scores depending on Molinari scores.
Emphasizing outcome, at least in certain recipient risk categories, might improve the longtime outcomes and might be integrated into allocation models.
目前的肝移植(LT)分配机制过度强调紧急情况,导致长期预后较差。效用被引入以在分配中认可预后。最近,莫利纳里提出了一种基于受者数据的预测结果模型。
本研究的目的是验证该模型,并将其与效用相结合以在分配中强调预后。
我们回顾性分析了2010年1月至2019年12月期间接受移植的734例患者。按照莫利纳里模型进行评分,评分总和与观察到的90天死亡率相关。效用计算为1年生存率乘以等待名单上3个月的死亡率。引入不同成分的权重,并计算效用曲线。根据最大效用确定终末期肝病模型(MELD)评分。
总共有120例患者(16.3%)在肝移植后90天内死亡。较高的MELD评分、肥胖和肝移植前的血液透析是已确认的危险因素。90天和12个月后的总体生存率分别为83.8%和77.4%。总体人群中,一般效用在MELD评分>35时达到峰值。根据莫利纳里评分,强调预后会将最大效用转移到较低的MELD评分。
强调预后,至少在某些受者风险类别中,可能会改善长期预后,并可能被纳入分配模型。